Metastatic Triple Negative Breast Cancer Clinical Trial
Official title:
An Open Label, Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
This study will evaluate the effectiveness and safety of the combination of two drugs, Veliparib and Lapatinib, given to participants with metastatic triple negative breast cancer that have undergone previous treatment. Veliparib is an investigational drug and has not been approved by the FDA while Lapatinib has been approved by the FDA for another type of breast cancer. All eligible participants will receive the study medications and not a placebo.
Breast cancer is the most commonly diagnosed cancer in American women. Metastatic breast cancer remains incurable partially due to the lack of targeted therapy for selected subsets of patients. There are five distinct subsets of breast cancer with unique biological profiles. Triple negative breast cancer (TNBC) is a subset with special clinical interest because of its significant percentage of occurrence (10-20% of all breast cancer diagnoses) and its poor prognosis. With no defined targeted therapy to date, this study seeks to investigate a therapeutic strategy based on specific molecular abnormalities in the tumor cells of TNBC. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02555657 -
Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
|
Phase 3 | |
| Completed |
NCT02834403 -
L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT03121352 -
Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03330847 -
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
|
Phase 2 | |
| Completed |
NCT03256344 -
Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
|
Phase 1 | |
| Recruiting |
NCT04739670 -
Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer
|
Phase 2 | |
| Withdrawn |
NCT01936961 -
Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors
|
N/A | |
| Completed |
NCT01238952 -
Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer
|
Phase 1 | |
| Completed |
NCT03577743 -
Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer
|
Phase 2 | |
| Completed |
NCT03411161 -
S 81694 Plus Paclitaxel in Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04149444 -
A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer
|
Phase 2 | |
| Withdrawn |
NCT05008510 -
P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .
|
Phase 2 | |
| Completed |
NCT04111510 -
Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer
|
Phase 2 | |
| Terminated |
NCT03055312 -
Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer
|
Phase 3 | |
| Recruiting |
NCT05029999 -
CD40 Agonist, Flt3 Ligand, and Chemotherapy in Triple Negative Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT03709446 -
Leflunomide in Previously Treated Metastatic Triple Negative Cancers
|
Phase 1/Phase 2 |